Advertisement
Screener

ProKidney Corp. (PROK) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

1.7 / 5 stars · 8/23 Roast Me

ProKidney Corp. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

ProKidney Corp. (PROK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-18

  • ProKidney Corp. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.40%, a 4.76% increase year-over-year.
  • ProKidney Corp. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.20%, a 0.00% change year-over-year.
  • ProKidney Corp. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.20%.
  • ProKidney Corp. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.40%, a 4.35% decline from fiscal 2024.
  • ProKidney Corp. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.60%, a 6.98% increase from fiscal 2023.
  • ProKidney Corp. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.30%, a 2.27% decline from fiscal 2022.
  • ProKidney Corp. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.40%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed
2025-12-314.40%
10-K · filed 2026-03-18
2025-06-304.40%
10-Q · filed 2025-08-12
2025-03-314.40%
10-Q · filed 2025-05-12
2024-12-314.60%
10-K · filed 2026-03-18
2024-09-304.60%
10-Q · filed 2024-11-12
2024-06-304.60%
10-Q · filed 2025-08-12
2024-03-314.20%
10-Q · filed 2025-05-12
2023-12-314.30%
10-K · filed 2025-03-17
4.70%
10-K · filed 2024-03-22
2023-09-304.30%
10-Q · filed 2024-11-12
2023-06-304.20%
10-Q · filed 2024-08-09
2023-03-314.20%
10-Q · filed 2024-05-10
2022-12-314.40%
10-K · filed 2024-03-22